Skip to main content
Biomedicines logoLink to Biomedicines
. 2021 Dec 31;10(1):80. doi: 10.3390/biomedicines10010080

Alterations in the Proteome and Phosphoproteome Profiles of Rat Hippocampus after Six Months of Morphine Withdrawal: Comparison with the Forebrain Cortex

Hana Ujcikova 1,*, Adam Eckhardt 2, Lucie Hejnova 3, Jiri Novotny 3, Petr Svoboda 1
Editor: Estela Castilla Ortega
PMCID: PMC8772819  PMID: 35052759

Abstract

The knowledge about proteome changes proceeding during protracted opioid withdrawal is lacking. Therefore, the aim of this work was to analyze the spectrum of altered proteins in the rat hippocampus in comparison with the forebrain cortex after 6-month morphine withdrawal. We utilized 2D electrophoretic workflow (Pro-Q® Diamond staining and Colloidal Coomassie Blue staining) which was preceded by label-free quantification (MaxLFQ). The phosphoproteomic analysis revealed six significantly altered hippocampal (Calm1, Ywhaz, Tuba1b, Stip1, Pgk1, and Aldoa) and three cortical proteins (Tubb2a, Tuba1a, and Actb). The impact of 6-month morphine withdrawal on the changes in the proteomic profiles was higher in the hippocampus—14 proteins, only three proteins were detected in the forebrain cortex. Gene Ontology (GO) enrichment analysis of differentially expressed hippocampal proteins revealed the most enriched terms related to metabolic changes, cytoskeleton organization and response to oxidative stress. There is increasing evidence that energy metabolism plays an important role in opioid addiction. However, the way how morphine treatment and withdrawal alter energy metabolism is not fully understood. Our results indicate that the rat hippocampus is more susceptible to changes in proteome and phosphoproteome profiles induced by 6-month morphine withdrawal than is the forebrain cortex.

Keywords: protracted morphine withdrawal, rat hippocampus, rat brain cortex, gel-based proteomics, energy metabolism, oxidative stress, nLC-MS/MS

1. Introduction

Morphine is still considered a frequently used opioid in the treatment of moderate to severe pain. However, repetitive clinical use has many negative side effects [1,2]. The analgesic effect is caused by the activation of the opioid receptors (ORs). It has a high affinity for µ-OR (MOR) and a lower affinity for κ-OR (KOR) and δ-OR (DOR) [3,4].

During the last years, we published several animal studies related to the consequences of morphine treatment and withdrawal. Bourova et al. [5] described that exposure of rats to increasing doses of morphine (10–50 mg/kg, 10 days) results in significant desensitization of μ-OR- and δ-OR-stimulated G protein response in the rat forebrain cortex. These findings were in agreement with the data published previously [6,7,8,9,10,11]. Ujcikova et al. [12] detected specific increased level of adenylyl cyclase I (8-fold) and adenylyl cyclase II (2.5-fold) in rat brain cortical plasma membrane samples after 10-day morphine treatment which returned to control level after 20 days of morphine withdrawal. There was no change in the expression level of other adenylyl cyclase isoforms (III-IX). Quantitative immunoblot analysis indicated the unchanged level of G protein α and β subunits: Gαi1/Gαi2, Gαi3, Gαo, Gαq/Gα11, Gαs, Gαz, and Gβ. The same applied to Na, K-ATPase, and caveolin-1 [12,13].

We applied 2D electrophoretic proteomic approach accompanied by label-free quantification to analyze the altered proteins in the rat brain after 10-day morphine administration followed by protracted drug abstinence [14,15,16,17]. The identified proteins were mainly involved in the change of energy metabolism, regulation of the cytoskeleton, signal transduction, oxidative stress pathways, and apoptotic pathways. Similar to our results, a number of studies indicated that chronic morphine treatment causes significant changes in the expression level of metabolic enzymes, cytoskeletal proteins, and apoptosis-related proteins [18,19,20,21,22,23,24,25,26,27]. These data may support the idea that long-term morphine treatment dysregulates brain energy homeostasis, increases the degree of neuroplasticity, and causes the state of brain cell discomfort [14,15].

Interestingly, we obtained the opposite results in the rat brain cortex and hippocampus. The number of altered proteins was decreased in the cortical samples and increased in the hippocampus after 20 days of morphine withdrawal [16]. Proteomic and phosphoproteomic comparison of the four rat brain parts (cortex, hippocampus, striatum, and cerebellum) isolated from animals after 3 months of drug abstinence demonstrated that withdrawal symptoms may last for weeks or even longer [17]. In the present study, we extended the withdrawal period from 3 to 6 months and applied gel-based proteomics to analyze the alterations in both protein expression and protein phosphorylation in the rat hippocampus and forebrain cortex. This could be a valuable addition to our previous study in which label-free quantification (MaxLFQ) was used to identify changes in the proteomic profiles of these brain parts [28]. Although shotgun proteomics may generate a large list of proteins, it does not bring information about protein isoforms and post-translational modifications. For this purpose, 2D gel electrophoresis is the only currently available proteomic technique [29].

2. Materials and Methods

2.1. Chemicals

Chemicals for 2D electrophoresis (Immobiline DryStrips, pH 3–11 NL, 13 cm) were obtained from Cytiva (Marlborough, MA, USA), InvitrogenTM (Pro-Q® Diamond Phosphoprotein Gel Stain and Gel Destaining Solution) and Sigma-Aldrich (St. Louis, MO, USA) as described by Ujcikova et al. [17].

2.2. Morphine Administration and Drug Withdrawal of Male Wistar Rats

Rats (8 weeks of age) were exposed to increasing doses of morphine (dissolved in 0.9% NaCl) for 10 days (10–50 mg/kg) in parallel with corresponding control animals according to our previously established protocols [5,12,14,15,16,17,28] approved by the Ministry of Education, Youth and Sports of the Czech Republic (license number MSMT-1479/2019–6). Male Wistar rats were housed in the group of 3 per plastic cage on a 12/12 light/dark cycle. Food and water were available ad libitum. Described procedures were performed in an agreement with national and institutional guidelines for the care and use of animals in laboratory research.

2.3. Preparation of Samples

According to our experience and considering the sufficient amount of biological material needed for analyses, we used 9 animals of each testing group for the isolation of the brain cortex, hippocampus, striatum and cerebellum. The tissue from 3 randomly selected animals within the same group was pooled into one sample to obtain three equal amounts of brain tissues.

Finally, we obtained six pooled hippocampal (M1, M2, M3, C1, C2, C3), six pooled cortical (M1, M2, M3, C1, C2, C3), six pooled striatal (M1, M2, M3, C1, C2, C3), and six pooled cerebellar (M1, M2, M3, C1, C2, C3) samples which were homogenized as described by Ujcikova et al. [17] and Drastichova et al. [28]. Protein concentration was determined by Lowry method.

2.4. Detection of Phosphoproteins by Pro-Q® Diamond Staining

Isoelectric focusing of samples containing 1 mg protein was performed according to our previously established scheme: 150 V for 5 h, 500 V for 1 h, 3500 V for 12 h, and 500 V for 3 h [15,16,17]. SDS-PAGE was followed by gel fixation in 250 mL of 50% methanol/10% acetic acid for 30 min and overnight with gentle agitation [30]. After three times washing in ultrapure water for 10 min, the gels were incubated in 160 mL of Pro-Q® Diamond stain solution for 120 min in the dark. Pro-Q® Diamond gel destaining solution was used three times for 30 min in the dark [17].

2.5. Scanning of Phosphorylated Proteins

2D gels were scanned by using Amersham Typhoon Biomolecular Imager (GE Healthcare). Laser excitation wavelength: 532 nm (green), emission filter wavelength: Cy3, 560–580 nm. Scan speed: normal, pixel size: 100 µm, voltage of the photo-multipliertube (PMT): 750 V.

2.6. Staining by Colloidal Coomassie Blue (CBB)

CBB staining was used for detection of protein spots on 2D gels and subsequent mass spectrometric analysis as described in [14,15,16].

2.7. Statistical Analysis

The PDQuestTM software (Bio-Rad, version 7.3.1, Hercules, CA, USA) was used for evaluation of 2D gels. Protein spots were then checked manually. Relative abundances of protein spots showing significant quantitative differences at least 1.4-fold (p ≤ 0.05) were selected for mass spectrometric analysis. p-values were calculated by using unpaired Student’s t-test and GraphPadPrism 8.3.0. Gene Ontology (GO) enrichment analysis of proteomic and phosphoproteomic profiles for rat brain hippocampus and cortex was performed using ShinyGO v0.74 tool in 20 October 2021 (bioinformatics.sdstate.edu/go, accessed on 20 October 2021); the p-value cut-off (FDR) was set to 0.05 for biological processes.

2.8. nLC-MS/MS

Protein spots were excised from the polyacrylamide gels and then analyzed as described in [17,31,32]. Briefly, after purification with STAGE-TIPs, peptide separation was achieved using a nano-LC device (Proxeon, Odense, Denmark) coupled to a maXis Q-TOF (quadrupole-time of flight) mass spectrometer with ultra-high resolution (Bruker Daltonics, Bremen, Germany). Appropriate software was used (HyStar 3.2 and MicroTOF control Version 3.0., ProteinScape 3.0 and DataAnalysis 4.0 (Bruker Daltonics, Billerica, MA, USA)) for data analysis. Only significant hits (MASCOT score ≥80 for proteins; ≥30 for peptides) were accepted. Proteins were identified by correlating tandem mass spectra with the UniProt/Swiss-Prot database (taxonomy = Rattus norvegicus). The MASCOT online search engine (http://www.matrixscience.com) was used. All nLC-MS/MS analyses were performed in duplicates (two samples per spot).

3. Results

3.1. Proteomic Analysis of the Rat Hippocampus Isolated from Animals after 6 Months of Morphine Withdrawal

3.1.1. Pro-Q® Diamond Staining and Colloidal Coomassie Blue Staining of 2D Gels

Pro-Q® Diamond staining and PDQuest analysis detected 82 protein spots in the rat hippocampus. Among these, six were significantly altered (p ≤ 0.05). nLC-MS/MS analysis identified three upregulated proteins (calmodulin-1 ↑2.3-fold, spot 1; 14-3-3 protein zeta/delta ↑2.4-fold, spot 2; tubulin alpha-1B chain ↑3.2-fold, spot 3) and three downregulated proteins (stress-induced-phosphoprotein 1 ↓3.5-fold, spot 4; phosphoglycerate kinase 1 ↓2.2-fold, spot 5; fructose-bisphosphate aldolase A ↓2.7-fold, spot 6), Figure 1a, Table 1a.

Figure 1.

Figure 1

Representative 2D gel maps of phosphorylated proteins (a) and total protein profiles (b) in the rat hippocampus isolated from animals after 6 months of morphine withdrawal. Red arrows and numbers show the significantly altered protein spots.

Table 1.

nLC-MS/MS analysis of significantly altered protein spots identified in the rat hippocampus (a,b) and cortex (c,d) isolated from animals after 6 months of morphine withdrawal.

Spot Accession Gene Protein Name Mascot Matched SC a MW b pI c Change p Value
Number Score Peptides [%] (kDa) (Fold)
(a) HIPPOCAMPUS Pro-Q® Diamond staining
1 P0DP29 Calm1 Calmodulin-1 2299.5 28 93.3 16.8 3.9 ↑2.3 0.0316
2 P63102 Ywhaz 14-3-3 protein zeta/delta 1654.2 25 74.7 27.8 4.6 ↑2.4 0.0014
3 Q6P9V9 Tuba1b Tubulin alpha-1B chain 1866.7 27 57.9 50.1 4.8 ↑3.2 0.0424
4 O35814 Stip1 Stress-induced phosphoprotein 1 1728.2 32 39.4 62.5 6.4 ↓3.5 0.0309
5 P16617 Pgk1 Phosphoglycerate kinase 1 2026.8 36 57.8 44.5 9.0 ↓2.2 0.0195
6 P05065 Aldoa Fructose-bisphosphate aldolase A 2243.8 35 80.2 39.3 9.2 ↓2.7 0.0084
(b) HIPPOCAMPUS Colloidal Coommassie Blue staining
1 P35704 Prdx2 Peroxiredoxin-2 429.6 8 33.8 21.8 5.2 ↓3.1 0.0036
2 P31044 Pebp1 Phosphatidylethanolamine-binding 988.5 13 62.6 20.8 5.4 ↓2.6 0.0004
protein 1
3 Q00981 Uchl1 Ubiquitin carboxyl-terminal hydrolase 1462.4 24 59.6 24.8 5.0 ↓2.0 0.0394
isozyme L1
4 F8WFM2 Napb Beta-soluble NSF attachment protein 1276.3 20 55.4 33.5 5.2 ↓2.4 0.0015
5 P54311 Gnb1 Guanine nucleotide-binding protein 728.3 12 33.2 37.4 5.6 ↓2.4 0.0045
G(I)/G(S)/G(T) subunit beta-1
6 O35179 Sh3gl2 Endophilin-A1 1368.9 28 34.4 39.9 5.1 ↓7.8 0.0363
7 P60711 Actb Actin, cytoplasmic 1 2492.6 38 62.7 41.7 5.2 ↓1.8 0.0293
8 P07335 Ckb Creatine kinase B-type 2008.6 27 57 42.7 5.3 ↓1.6 0.0402
9 P07335 Ckb Creatine kinase B-type 2337.6 34 65.4 42.7 5.3 ↓2.3 0.0026
10 G3V7C6 Tubb4b Tubulin beta chain 2983.9 37 49.8 61.1 4.6 ↓1.9 0.0358
11 P23565 Ina Alpha-internexin 2688.1 41 75.6 56.1 5.1 ↓2.4 0.0117
12 F1M953 Hspa9 Stress-70 protein, mitochondrial 2772.9 43 41.7 73.7 5.8 ↓3.1 0.0127
13 G3V7C6 Tubb4b Tubulin beta chain 1809.5 23 40.5 61.1 4.6 ↓6.1 0.0175
14 P31399 Atp5pd ATP synthase subunit d, mitochondrial 1680.6 23 67.7 18.8 6.2 ↑6.7 0.0011
15 O88767 Park7 Parkinson disease protein 7 homolog 1106.3 15 70.4 20 6.4 ↑2.0 0.0324
16 P48500 Tpi1 Triosephosphate isomerase 829.1 12 53 26.8 7.7 ↑1.9 0.0348
(c) CORTEX Pro-Q® Diamond staining
1 P85108 Tubb2a Tubulin beta-2A chain 3071.4 37 73 49.9 4.6 ↓2.4 0.0103
2 P68370 Tuba1a Tubulin alpha-1A chain 1538.3 21 47 50.1 4.8 ↓3.7 0.0406
3 P60711 Actb Actin, cytoplasmic 1 1532.3 23 50.9 41.7 5.2 ↓2.7 0.0284
(d) CORTEX Colloidal Coommassie Blue staining
1 P0DP29 Calm1 Calmodulin-1 1670.9 18 74.5 16.8 3.9 ↓2.0 0.0478
2 P37377 Snca Alpha-synuclein 1287.2 16 80 14.5 4.6 ↓1.4 0.0114
3 Q99NA5 Idh3a Isocitrate dehydrogenase [NAD] subunit 830.1 9 28 39.6 6.5 ↑2.4 0.0252
alpha, mitochondrial

a sequence coverage, b theoretical molecular weight, c theoretical isoelectric point.

Colloidal Coomassie Blue staining (CBB) revealed 111 protein spots, 16 spots were found to differ significantly. Eleven altered proteins were downregulated (peroxiredoxin-2 ↓3.1-fold, spot 1; phosphatidylethanolamine-binding protein 1 ↓2.6-fold, spot 2; ubiquitin carboxyl-terminal hydrolase isozyme L1 ↓2.0-fold, spot 3; beta-soluble NSF attachment protein ↓2.4-fold, spot 4; guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 ↓2.4-fold, spot 5; endophilin-A1 ↓7.8-fold, spot 6; actin, cytoplasmic 1 ↓1.6-fold, spot 7; creatine kinase B-type ↓1.6-fold and ↓2.3-fold, spot 8 and spot 9; tubulin beta chain ↓1.9-fold and ↓6.1-fold, spot 10 and spot 13; alpha internexin ↓2.4-fold, spot 11; stress-70 protein, mitochondrial ↓3.1-fold, spot 12), and three proteins were upregulated (ATP synthase subunit d, mitochondrial ↑6.7-fold, spot 14; Parkinson disease protein 7 homolog ↑2.0-fold, spot 15; triosephosphate isomerase ↑1.9-fold, spot 16), Figure 1b, Table 1b.

According to the current annotations (https://www.uniprot.org, accessed on 20 October 2021) in the UniProt database, the identified hippocampal proteins were involved in metabolism (5), cytoskeleton organization (4), signal transduction (3), protein folding (3), response to oxidative stress (3), brain development (3), transport (3), aging (2), apoptosis (1), and protein ubiquitination (1) (Figure 2b; Table 2a,b).

Figure 2.

Figure 2

Subcellular localization (a,c) and function (b,d) of altered proteins identified in the rat hippocampus (upper panels) and cortex (lower panels) isolated from animals after 6 months of morphine withdrawal; according to the current annotations (https://www.uniprot.org) in the UniProt database.

Table 2.

Subcellular localization and function of altered proteins identified in the rat hippocampus (a,b) and cortex (c,d) isolated from animals after 6 months of morphine withdrawal; according to the current annotations (https://www.uniprot.org) in the UniProt database.

Spot Accession Protein Name Change Subcellular Localization GO-Molecular Functions, Biological Processes
Number (Fold)
(a) HIPPOCAMPUS Pro-Q® Diamond staining
1 P0DP29 Calmodulin-1 ↑2.3 Cytoplasm, cytoskeleton Calcium-mediated signaling, activation
of adenylate cyclase activity, regulation
of cytokinesis
2 P63102 14-3-3 protein zeta/delta ↑2.4 Cytoplasm, melanosome Signal transducing adaptor protein
3 Q6P9V9 Tubulin alpha-1B chain ↑3.2 Cytoplasm, cytoskeleton Cell shape and movement
4 O35814 Stress-induced phosphoprotein 1 ↓3.5 Cytoplasm, nucleus Chaperone binding
5 P16617 Phosphoglycerate kinase 1 ↓2.2 Cytoplasm Energy metabolism (glycolysis)
6 P05065 Fructose-bisphosphate aldolase A ↓2.7 Cytoplasm Energy metabolism (glycolysis)
(b) HIPPOCAMPUS Colloidal Coommassie Blue staining
1 P35704 Peroxiredoxin-2 ↓3.1 Cytoplasm Antioxidant, response to oxidative stress
2 P31044 Phosphatidylethanolamine-binding ↓2.6 Cytoplasm, cell membrane Hippocampus development, aging, response
protein 1 to oxidative stress, MAPK cascade
3 Q00981 Ubiquitin carboxyl-terminal hydrolase ↓2.0 Cytoplasm, endoplasmic reticulum Protein ubiquitination, axonogenesis
isozyme L1
4 F8WFM2 Beta-soluble NSF attachment protein ↓2.4 Cell membrane ER-Golgi transport, protein transport
5 P54311 Guanine nucleotide-binding protein ↓2.4 Cell membrane, cytoplasm Signal transducer
G(I)/G(S)/G(T) subunit beta-1
6 O35179 Endophilin-A1 ↓7.8 Cytoplasm, endosome, cell membrane Endocytosis, regulation of receptor internalization
7 P60711 Actin, cytoplasmic 1 ↓1.8 Cytoplasm, cytoskeleton, nucleus Cell shape and movement
8,9 P07335 Creatine kinase B-type ↓1.6, ↓2.3 Cytoplasm Brain development, creatine metabolism
10,13 G3V7C6 Tubulin beta chain ↓1.9, ↓6.1 Cytoplasm, cytoskeleton Cell shape and movement
11 P23565 Alpha-internexin ↓2.4 Cytoplasm, cytoskeleton Cytoskeleton organization, developmental protein
12 F1M953 Stress-70 protein, mitochondrial ↓3.1 Mitochondrion Chaperone
14 P31399 ATP synthase subunit d, mitochondrial ↑6.7 Mitochondrion ATP metabolic process, hydrogen ion transport
15 O88767 Parkinson disease protein 7 homolog ↑2.0 Cell membrane, cytoplasm, nucleus, Chaperone, aging, inflammatory response, stress
endoplasmic reticulum response, negative regulation of apoptosis
16 P48500 Triosephosphate isomerase ↑1.9 Cytoplasm Energy metabolism (glycolysis)
(c) CORTEX Pro-Q® Diamond staining
1 P85108 Tubulin beta-2A chain ↓2.4 Cytoplasm, cytoskeleton Cell shape and movement
2 P68370 Tubulin alpha-1A chain ↓3.7 Cytoplasm, cytoskeleton Cell shape and movement
3 P60711 Actin, cytoplasmic 1 ↓2.7 Cytoplasm, cytoskeleton, nucleus Cell shape and movement
(d) CORTEX Colloidal Coommassie Blue staining
1 P0DP29 Calmodulin-1 ↓2.0 Cytoplasm, cytoskeleton Calcium-mediated signaling, activation of adenylate cyclase activity, regulation of cytokinesis
2 P37377 Alpha-synuclein ↓1.4 Cytoplasm, cell membrane, nucleus, secreted Chaperone, response to oxidative stress, regulation of synaptic vesicle trafficking, regulation of neurotransmitter release
3 Q99NA5 Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial ↑2.4 Mitochondrion Krebs cycle

3.1.2. GO Enrichment Analysis of Altered Hippocampal Proteins

GO enrichment analysis of 20 significantly differentially expressed hippocampal proteins was carried out using the ShinyGO v0.74 tool (bioinformatics.sdstate.edu/go). The top thirty most significantly enriched GO terms for biological processes were summarized in hierarchical clustering tree, see Figure 3. The most enriched GO terms were related to metabolic changes: phosphorus metabolic process, phosphate-containing compound metabolic process, ATP metabolic process, methylglyoxal metabolic process, generation of precursor metabolites and energy, nucleoside phosphate metabolic process, nucleotide metabolic process; cytoskeleton organization: postsynaptic cytoskeleton organization, establishment of localization in cell, postsynaptic actin cytoskeleton organization, and oxidative stress: removal of superoxide radicals, response to superoxide, response to oxygen radical. The detailed data of these GO enriched terms are listed in Table 3, including enrichment FDR values and gene names of altered proteins associated with GO terms.

Figure 3.

Figure 3

Hierarchical clustering tree summarizing the top 30 most significantly enriched GO terms that were identified in rat hippocampus. The analyzed dataset was consisted of 20 significantly differentially expressed hippocampal proteins.

Table 3.

GO enrichment analysis for significantly upregulated and downregulated proteins identified in the rat hippocampus isolated from animals after 6 months of morphine withdrawal; carried out using the ShinyGO v0.74 tool (bioinformatics.sdstate.edu/go). The top thirty most significantly enriched GO terms for biological processes are listed.

Pathways Enrichment FDR Pathway Genes Name of Genes in List
Genes in List
Phosphorus metabolic process 0.000454130956700965 2813 12 Atp5pd, Aldoa, Uchl1, Prdx2, Calm1, Sh3gl2, Ywhaz, Ckb, Tpi1, Park7, Pgk1, Actb
Phosphate-containing compound metabolic process 0.000454130956700965 2798 12 Atp5pd, Aldoa, Uchl1, Prdx2, Calm1, Sh3gl2, Ywhaz, Ckb, Tpi1, Park7, Pgk1, Actb
Phosphorylation 0.00109269868079895 2072 10 Aldoa, Uchl1, Prdx2, Sh3gl2, Ywhaz, Tpi1, Park7, Pgk1, Actb, Atp5pd
ATP metabolic process 0.00109269868079895 272 5 Atp5pd, Aldoa, Tpi1, Park7, Pgk1
Methylglyoxal metabolic process 0.001813238441941 5 2 Park7, Aldoa
Generation of precursor metabolites and energy 0.00432203205106559 397 5 Aldoa, Tpi1, Park7, Pgk1, Atp5pd
Nucleoside phosphate metabolic process 0.00464706222526931 428 5 Atp5pd, Aldoa, Tpi1, Park7, Pgk1
Nucleotide metabolic process 0.00464706222526931 419 5 Atp5pd, Aldoa, Tpi1, Park7, Pgk1
Postsynaptic cytoskeleton organization 0.00556835599926725 13 2 Ina, Actb
Organophosphate metabolic process 0.00556835599926725 820 6 Atp5pd, Aldoa, Ckb, Tpi1, Park7, Pgk1
Establishment of localization in cell 0.00556835599926725 1630 8 Calm1, Ywhaz, Uchl1, Napb, Park7, Hspa9, Actb, Atp5pd
Nucleobase-containing small molecule metabolic process 0.00556835599926725 473 5 Atp5pd, Aldoa, Tpi1, Park7, Pgk1
Postsynaptic actin cytoskeleton organization 0.00556835599926725 13 2 Ina, Actb
Pyruvate metabolic process 0.00698656482715899 121 3 Aldoa, Tpi1, Pgk1
Glycolytic process 0.00698656482715899 102 3 Aldoa, Tpi1, Pgk1
Nucleoside diphosphate phosphorylation 0.00698656482715899 120 3 Aldoa, Tpi1, Pgk1
ATP generation from ADP 0.00698656482715899 103 3 Aldoa, Tpi1, Pgk1
Purine nucleoside diphosphate metabolic process 0.00698656482715899 113 3 Aldoa, Tpi1, Pgk1
Purine ribonucleoside diphosphate metabolic process 0.00698656482715899 113 3 Aldoa, Tpi1, Pgk1
Ribonucleoside diphosphate metabolic process 0.00698656482715899 116 3 Aldoa, Tpi1, Pgk1
Removal of superoxide radicals 0.00698656482715899 18 2 Prdx2, Park7
Response to chemical 0.00698656482715899 4423 12 Ywhaz, Gnb1, Uchl1, Prdx2, Calm1, Park7, Ina, Stip1, Actb, Tuba1b, Atp5pd, Aldoa
Response to superoxide 0.00698656482715899 21 2 Prdx2, Park7
Response to oxygen radical 0.00698656482715899 21 2 Prdx2, Park7
ADP metabolic process 0.00698656482715899 108 3 Aldoa, Tpi1, Pgk1
Nucleotide phosphorylation 0.00698656482715899 122 3 Aldoa, Tpi1, Pgk1
Cellular response to chemical stimulus 0.00698656482715899 2498 9 Gnb1, Uchl1, Prdx2, Park7, Ina, Stip1, Actb, Tuba1b, Atp5pd
Cellular response to oxygen radical 0.00698656482715899 19 2 Prdx2, Park7
Cellular response to superoxide 0.00698656482715899 19 2 Prdx2, Park7
Purine ribonucleotide metabolic process 0.00726512653650191 327 4 Atp5pd, Aldoa, Tpi1, Pgk1

3.2. Proteomic Analysis of the Rat Forebrain Cortex Isolated from Animals after 6 Months of Morphine Withdrawal

3.2.1. Pro-Q® Diamond Staining and Colloidal Coomassie Blue Staining of 2D Gels

The 83 phosphorylated protein spots were detected in the rat brain cortex, only three were significantly downregulated: tubulin beta-2A chain ↓2.4-fold, spot 1; tubulin alpha-1A chain ↓3.7-fold, spot 2 and actin, cytoplasmic 1 ↓2.7-fold, spot 3; Figure 4a, Table 1c.

Figure 4.

Figure 4

Representative 2D gel maps of phosphorylated proteins (a) and total protein profiles (b) in the rat forebrain cortex isolated from animals after 6 months of morphine withdrawal. Red arrows and numbers show the significantly altered protein spots.

CBB staining revealed 87 protein spots in cortical 2D gels, only three of these were significantly altered. nLC-MS/MS analysis identified two proteins with decreased level (calmodulin 1 ↓2.0-fold, spot 1; alpha-synuclein ↓1.4-fold, spot 2) and one upregulated protein: mitochondrial isocitrate dehydrogenase [NAD] subunit alpha ↑2.4-fold, spot 3; Figure 4b, Table 1d.

According to the current annotations (https://www.uniprot.org) in the UniProt database, the identified cortical proteins were functionally related to cytoskeleton organization (3), vesicle endocytosis (2), metabolism (1), signal transduction (1), response to oxidative stress (1), and protein folding (1) (Figure 2d; Table 2c,d).

3.2.2. GO Enrichment Analysis of Altered Cortical Proteins

GO enrichment analysis of six significantly differentially expressed cortical proteins (Table 1c,d) was carried out using the ShinyGO v0.74 tool (bioinformatics.sdstate.edu/go). The top ten most significantly enriched GO terms for biological processes were summarized in hierarchical clustering tree (Figure 5). The most enriched GO terms were related to vesicle endocytosis: presynaptic endocytosis, synaptic vesicle endocytosis, synaptic vesicle recycling, synaptic vesicle cycle, vesicle-mediated transport in synapse, and regulation of catecholamine uptake. The detailed data of these GO enriched terms are listed in Table 4, including enrichment FDR values and gene names of altered proteins associated with GO terms.

Figure 5.

Figure 5

Hierarchical clustering tree summarizing the top 10 most significantly enriched GO terms that were identified in rat forebrain cortex. The analyzed dataset was consisted of 6 significantly differentially expressed cortical proteins.

Table 4.

GO enrichment analysis for significantly upregulated and downregulated proteins identified in the rat forebrain cortex isolated from animals after 6 months of morphine withdrawal; carried out using the ShinyGO v0.74 tool (bioinformatics.sdstate.edu/go). The top ten most significantly enriched GO terms for biological processes are listed.

Pathways Enrichment FDR Pathway Genes Name of Genes in List
Genes in List
Presynaptic endocytosis 0.0000317791916695507 41 3 Snca, Actb, Calm1
Synaptic vesicle endocytosis 0.0000317791916695507 41 3 Snca, Actb, Calm1
Regulation of norepinephrine uptake 0.0000317791916695507 2 2 Snca, Actb
Synaptic vesicle recycling 0.0000411603443103439 49 3 Snca, Actb, Calm1
Norepinephrine uptake 0.00014973418795375 6 2 Snca, Actb
Catecholamine uptake 0.000648303871273433 13 2 Snca, Actb
Synaptic vesicle cycle 0.000655582495341169 147 3 Snca, Actb, Calm1
Vesicle-mediated transport in synapse 0.000739942307588717 160 3 Snca, Actb, Calm1
Norepinephrine transport 0.000753222666338899 17 2 Snca, Actb
Regulation of transmembrane transporter activity 0.00113861317223078 199 3 Calm1, Snca, Actb

3.3. Proteomic Analysis of the Rat Striatum and Cerebellum Isolated from Animals after 6 Months of Morphine Withdrawal

3.3.1. Colloidal Coomassie Blue Protein Staining of Striatal 2D Gels

CBB-stained 2D gels revealed 152 protein spots in the rat striatum, ten proteins with significantly changed expression level were identified by nLC-MS/MS analysis. Among these, seven proteins were downregulated: calmodulin-1 ↓2.3-fold, spot 1; l-lactate dehydrogenase B chain ↓1.4-fold, spot 3; malate dehydrogenase, cytoplasmic ↓1.8-fold, spot 4; albumin ↓2.4-fold, spot 7; dihydropyrimidinase-related protein 2 ↓1.7-fold and ↓2.0-fold, spot 8 and spot 9; nucleoside diphosphate kinase B ↓2.0-fold, spot 10, and elongation factor 1-alpha ↓3.1-fold, spot 11. Only three proteins were upregulated: peroxiredoxin-2 ↑1.8-fold, spot 2; actin, cytoplasmic 1 ↑3.3-fold, spot 5 and heat shock cognate 71 kDa protein ↑2.5-fold, spot 6; Figure 6a, Table 5a.

Figure 6.

Figure 6

Representative 2D gel maps of total protein profiles in the rat striatum (a, upper panels) and cerebellum (b, lower panels) isolated from animals after 6 months of morphine withdrawal. Red arrows and numbers show the significantly altered protein spots.

Table 5.

nLC-MS/MS analysis of significantly altered protein spots identified in the rat striatum (a) and cerebellum (b) isolated from animals after 6 months of morphine withdrawal.

Spot Accession Gene Protein Name Mascot Matched SC a MW b pI c Change p Value
Number Score Peptides [%] (kDa) (Fold)
(a) STRIATUM Colloidal Coommassie Blue staining
1 P0DP29 Calm1 Calmodulin-1 1050.8 15 74.5 16.8 3.9 ↓2.3 0.0079
2 P35704 Prdx2 Peroxiredoxin-2 388.2 7 31.3 21.8 5.2 ↑1.8 0.0214
3 P42123 Ldhb L-lactate dehydrogenase B chain 1159.9 20 41.3 36.6 5.6 ↓1.4 0.0483
4 O88989 Mdh1 Malate dehydrogenase, cytoplasmic 808.2 14 44.9 36.5 6.2 ↓1.8 0.0326
5 P60711 Actb Actin, cytoplasmic 1 1304.1 24 44.5 41.7 5.2 ↑3.3 0.0258
6 P63018 Hspa8 Heat shock cognate 71 kDa protein 1336.6 23 31.6 70.8 5.2 ↑2.5 0.0050
7 P02770 Alb Albumin 651.8 12 18.3 68.7 6.1 ↓2.4 0.0115
8 P47942 Dpysl2 Dihydropyrimidinase-related protein 2 1104.7 17 35.5 62.2 5.9 ↓1.7 0.0352
9 P47942 Dpysl2 Dihydropyrimidinase-related protein 2 1997.6 31 56.3 62.2 5.9 ↓2.0 0.0244
10 P19804 Nme2 Nucleoside diphosphate kinase B 575.2 11 59.2 17.3 7.8 ↓2.0 0.0458
11 M0R757 LOC100360413 Elongation factor 1-alpha 548.1 12 21.2 50.1 9.7 ↓3.1 0.0030
(b) CEREBELLUM Colloidal Coommassie Blue staining
1 P61983 Ywhag 14-3-3 protein gamma 1065.1 20 49.4 28.3 4.7 ↓3.8 0.0451
2 P62260 Ywhae 14-3-3 protein epsilon 1373.3 23 49.8 29.2 4.5 ↓2.7 0.0214
3 P85969 Napb Beta-soluble NSF attachment protein 418.7 9 26.6 33.4 5.2 ↓1.6 0.0172
4 P54311 Gnb1 Guanine nucleotide-binding protein 497.7 9 22.9 37.4 5.6 ↓4.4 0.0035
G(I)/G(S)/G(T) subunit beta-1
5 P42123 Ldhb L-lactate dehydrogenase B chain 1288.1 22 43.7 36.6 5.6 ↓1.9 0.0471
6 P07335 Ckb Creatine kinase B-type 1531.4 22 53.8 42.7 5.3 ↓1.5 0.0246
7 Q6P9V9 Tuba1b Tubulin alpha-1B chain 1209.4 21 53.7 50.1 4.8 ↓2.1 0.0041
8 P63018 Hspa8 Heat shock cognate 71 kDa protein 2437.8 37 45.5 70.8 5.2 ↓2.1 0.0072
9 P47942 Dpysl2 Dihydropyrimidinase-related protein 2 1684.2 25 48.8 62.2 5.9 ↓1.8 0.0174
10 P09117 Aldoc Fructose-bisphosphate aldolase C 1956.9 28 59 39.3 6.8 ↓3.0 0.0053
11 P48500 Tpi1 Triosephosphate isomerase 859.3 12 50.6 26.8 7.7 ↓2.2 0.0200

a sequence coverage, b theoretical molecular weight, c theoretical isoelectric point.

According to the current annotations (https://www.uniprot.org) in the UniProt database, the altered striatal proteins were found to be functionally related to metabolism (3), RNA processing (3), cytoskeleton organization (2), signal transduction (1), response to oxidative stress (1), protein folding (1), aging (1), brain development (1), and apoptosis (1) (Figure 7b; Table 6a).

Figure 7.

Figure 7

Subcellular localization (a,c) and function (b,d) of altered proteins identified in the rat striatum (upper panels) and cerebellum (lower panels) isolated from animals after 6 months of morphine withdrawal; according to the current annotations (https://www.uniprot.org) in the UniProt database.

Table 6.

Subcellular localization and function of altered proteins identified in the rat striatum (a) and cerebellum (b) isolated from animals after 6 months of morphine withdrawal; according to the current annotations (https://www.uniprot.org) in the UniProt database.

Spot Accession Protein Name Change Subcellular Localization GO-Molecular Functions, Biological Processes
Number (Fold)
(a) STRIATUM Colloidal Coommassie Blue staining
1 P0DP29 Calmodulin-1 ↓2.3 Cytoplasm, cytoskeleton Calcium-mediated signaling, activation
of adenylate cyclase activity, regulation
of cytokinesis
2 P35704 Peroxiredoxin-2 ↑1.8 Cytoplasm Antioxidant, response to oxidative stress
3 P42123 L-lactate dehydrogenase B chain ↓1.4 Cytoplasm, mitochondrion Pyruvate metabolic process
4 O88989 Malate dehydrogenase, cytoplasmic ↓1.8 Cytoplasm Krebs cycle
5 P60711 Actin, cytoplasmic 1 ↑3.3 Cytoplasm, cytoskeleton, nucleus Cell shape and movement
6 P63018 Heat shock cognate 71 kDa protein ↑2.5 Cell membrane, cytoplasm, nucleus Protein folding, RNA processing, aging
7 P02770 Albumin ↓2.4 Secreted Transporter, apoptosis
8,9 P47942 Dihydropyrimidinase-related protein 2 ↓1.7,↓2.0 Cytoplasm, cytoskeleton, cell Brain development, neurogenesis, cell
membrane movement
10 P19804 Nucleoside diphosphate kinase B ↓2.0 Cytoplasm, nucleus Nucleotide metabolism, transcription
11 M0R757 Elongation factor 1-alpha ↓3.1 Cell membrane, cytoplasm, nucleus Translation
(b) CEREBELLUM Colloidal Coommassie Blue staining
1 P61983 14-3-3 protein gamma ↓3.8 Cytoplasm Signal transducing adaptor protein
2 P62260 14-3-3 protein epsilon ↓2.6 Cytoplasm, nucleus Signal transducing adaptor protein, brain
development
3 P85969 Beta-soluble NSF attachment protein ↓1.6 Cell membrane ER-Golgi transport, protein transport
4 P54311 Guanine nucleotide-binding protein ↓4.4 Cell membrane, cytoplasm Signal transduction
G(I)/G(S)/G(T) subunit beta-1
5 P42123 L-lactate dehydrogenase B chain ↓1.9 Cytoplasm, cell membrane, Pyruvate metabolic process
mitochondrion
6 P07335 Creatine kinase B-type ↓1.5 Cytoplasm Brain development, creatine metabolism
7 Q6P9V9 Tubulin alpha-1B chain ↓2.1 Cytoplasm, cytoskeleton Cell shape and movement
8 P63018 Heat shock cognate 71 kDa protein ↓2.1 Cell membrane, cytoplasm, nucleus Protein folding, RNA processing, aging
9 P47942 Dihydropyrimidinase-related protein 2 ↓1.8 Cytoplasm, cytoskeleton, cell Brain development, neurogenesis, cell
membrane movement
10 P09117 Fructose-bisphosphate aldolase C ↓3.0 Cytoplasm Energy metabolism (glycolysis), aging, apoptosis
11 P48500 Triosephosphate isomerase ↓2.2 Cytoplasm Energy metabolism (glycolysis)

3.3.2. Colloidal Coomassie Blue Protein Staining of Cerebellar 2D Gels

The total number of 122 protein spots were detected in the rat cerebellum, eleven proteins were significantly downregulated: 14-3-3 protein gamma ↓3.8-fold, spot 1; 14-3-3 protein epsilon ↓2.6-fold, spot 2; beta-soluble NSF attachment protein ↓1.6-fold, spot 3; guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 ↓4.4-fold, spot 4; l-lactate dehydrogenase B chain ↓1.9-fold, spot 5; creatine kinase ↓1.5-fold, spot 6; tubulin alpha-1B chain ↓2.1-fold, spot 7; heat shock cognate 71 kDa protein ↓2.1-fold, spot 8; dihydropyrimidinase-related protein 2 ↓1.8-fold, spot 9; fructose-bisphosphate aldolase C ↓3.0-fold, spot 10 and triosephosphate isomerase ↓2.2-fold, spot 11. Upregulation was not detected (Figure 6b; Table 5b).

According to the current annotations (https://www.uniprot.org) in the UniProt database, the identified cerebellar proteins with changed expression level were involved in metabolism (4), signal transduction (3), brain development (3), cytoskeleton organization (2), aging (2), protein transport (1), protein folding (1), RNA processing (1), and apoptosis (1) (Figure 7d; Table 6b).

4. Discussion

During the last years, we applied 2D electrophoresis and label-free quantification to find the significant alterations in protein expression in the rat brain cortex and hippocampus after chronic morphine treatment (10–50 mg/kg, 10 days) followed by different withdrawal periods (3 weeks, 3 months, 6 months) [15,16,17,28]. The aim of this work was to analyze the spectrum of altered proteins in selected rat brain regions after 6-month morphine withdrawal. Our study could have two main limitations. First, some animals could be lost during morphine administration and withdrawal. For that reason, we had three extra animals in each testing group. Second, proteomic analyses require a large amount of tissue. For this purpose, we selected the stated brain regions (cortex, hippocampus, striatum, and cerebellum). This selection provided us with a relatively large amount of biological material.

2D-DIGE analysis of the rat hippocampus showed that 10-day morphine administration results in a significant change of six proteins functionally related to metabolism, cytoskeleton organization, neuronal plasticity, apoptosis, and oxidative stress. Interestingly, the number of differentially regulated proteins was increased to 13 after 3 weeks of drug abstinence. Moreover, the level of α-synuclein (Snca), β-synuclein (Sncb), α-enolase (Eno1), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) persisted altered for 3 weeks since the withdrawal of morphine [16]. Ten proteins were identified in hippocampal 2D CBB-stained gels 3 months after cessation of 10-day morphine treatment; 14 proteins were significantly hypophosphorylated [17]. Among these, several glycolytic enzymes, such as GAPDH, Eno1, phosphoglycerate mutase 1 (Pgam1), triosephosphate isomerase (Tpi1) and fructose-bisphosphate aldolase A (Aldoa) were decreased. In this work, the impact of 6-month morphine withdrawal on the change of total protein composition was higher-14 proteins were identified (Figure 1b; Table 1b). On the other hand, the number of dysregulated phosphoproteins was reduced from 14 to 6 (Figure 1a; Table 1a). The amount of glycolytic enzymes with significantly changed expression level was not so eminent. Pro-Q® Diamond staining revealed downregulation of Aldoa and an increased level of Tpi1 was detected by CBB protein staining.

Previous studies of other authors have shown that enzymes involved in cellular metabolisms, such as glycolysis and Krebs cycle were altered in opioid-abusing patients and animal models [33,34]. Among the glycolytic enzymes, GAPDH is of particular interest. Its post-translational modifications may contribute to numerous cellular functions, including intracellular transport, cytoskeleton plasticity, heme chaperoning, transcription, and apoptosis [18,35,36,37,38,39,40]. However, its role in apoptosis is not clear. Some studies describe its proapoptotic function, others a protective role [41]. One of the typical features of GAPDH is its use as a loading marker in hundreds of studies. Notably, it was shown that the quantity of GAPDH can vary under stressful conditions [42].

Decreased level of superoxide dismutase [Cu-Zn] (Sod1) was detected in our hippocampal samples after 3 weeks of drug abstinence [16]. In this work, 6-month morphine withdrawal revealed downregulation of peroxiredoxin-2 (Prdx2) and upregulation of Parkinson disease protein 7 homolog (Park7), see Table 1b. Park 7 is involved in the protection against oxidative stress [43]. Due to its protective role, Park 7 represents an ideal possible therapeutic target for Parkinson’s disease (PD) and neurodegeneration [44]. We may hypothesize that stress-related pathways become activated during opioid withdrawal and can persist for several months after cessation of morphine administration.

Morphine could participate in the development of oxidative stress by promoting the formation of free radicals or reducing the activity of the antioxidant defense system which maintain redox homeostasis. Both these ways of action can be possibly combined [45]. Among the most important molecules playing a crucial role in cell protection against oxidative damage belong enzymes such as superoxide dismutase, glutathione peroxidase, catalase, and tripeptide glutathione [46]. The activity of antioxidant enzymes is closely associated with the production of reactive oxygen species (ROS) and reactive nitrogen species (RNS) that may lead to oxidative damage of DNA, lipids and proteins [47,48]. Results obtained by Motaghinejad et al. [49] showed that subcutaneous injection of morphine to rats significantly increased lipid peroxidation and decreased the activities of superoxide dismutase and glutathione peroxidase. Abdel-Zaher et al. [50] reported that glutamate levels and lipid peroxide malondialdehyde levels were significantly increased in the brain of morphine-treated mice. The impact of morphine on cellular redox balance may depend on multiple factors, such as species, age and sex of an organism, type of tissue, dosage, and length of usage [51].

The number of altered phosphorylated cytoskeletal proteins in the rat hippocampus was decreased from four (hypophosphorylation of F-actin-capping subunit beta (Capzb); actin, cytoplasmic 2 (Actg1); glial fibrillary acidic protein (GFAP) and tubulin alpha-1A chain (Tuba1a)) to one hyperphosphorylated tubulin alpha-1B chain (Tuba1b) when compared the period of abstinence 3 and 6 months. The change in protein expression was almost similar after 3 or 6 months of drug withdrawal and resulted in a decreased level of tubulin beta-4B chain (Tubb4b), tubulin polymerization promoting protein (Tppp), actin, cytoplasmic 1 (Actb), tubulin beta chain (Tubb4b), and alpha-internexin (Ina). These findings suggest that protracted morphine abstinence may cause long-term homeostatic changes in hippocampal plasticity [52]. However, according to our unpublished behavioral studies, we did not find significant differences between morphine-withdrawn and control animals. We may speculate that proteomic changes in the rat hippocampus after 6 months of morphine withdrawal do not require alterations in a certain behavior or functional state.

Twenty-eight significantly altered proteins were detected in the rat brain cortex after treatment with morphine for 10 days, this amount was reduced to 14 proteins after 3 weeks of abstinence [15], to 10 proteins after 3-month morphine withdrawal [17] and to only three proteins after 6-month drug abstinence. Chronic morphine treatment resulted in the decreased level of several glycolytic enzymes, such as Tpi1, Pgam1, GAPDH, Aldoa, pyruvate kinase PKM (Pkm), and phosphoglycerate kinase 1 (Pgk1). The expression level of Pkm, Pgk1 and GAPDH persisted decreased for 3 months of drug withdrawal and was not altered after 6 months of abstinence. It would be useful to confirm whether proteomics-indicated alterations in enzyme levels reflect changes in their activity. The change in protein expression does not necessarily mean the change in functional activity, as described by Bodzon-Kulakowska et al. [53] and Antolak et al. [26]. We assume that simultaneous alterations in both features may represent new insight into brain energy homeostasis.

Increasing evidence suggests that the striatum and cerebellum participate in drug addiction [54,55,56,57,58]. As a complement to proteomic analyses of rat hippocampus and cortex, we also performed the screening of protein alterations in the rat striatum and cerebellum after 6-month morphine withdrawal. Interestingly, the number of altered proteins was increased in both the striatum and cerebellum after 6-month drug withdrawal in comparison with the effect of 3-month morphine abstinence. In the striatum, the number of differentially expressed proteins was increased from 7 to 10 while in the cerebellum from 4 to 11. The majority of changes were related to metabolic alterations (L-lactate dehydrogenase B chain (Ldhb), malate dehydrogenase (Ldh1), creatine kinase B-type (Ckb), fructose-bisphosphate aldolase C (Aldoc), and Tpi1) (Figure 6; Table 6a,b). Taken together, our results suggest that protracted morphine withdrawal causes significant proteomic changes in the energy metabolism of different rat brain parts. We assume that deeper metabolic investigation into the brain structures may reveal numerous differences in glucose metabolism, the tricarboxylic acid cycle (TCA) and fatty acid metabolism. In addition, we may expect changes in metabolites related to antioxidant and nucleotide pathways. However, detailed studies are missing.

5. Conclusions

Our data show that the rat hippocampus is more affected than the forebrain cortex in both protein phosphorylation and protein expression by 6-month morphine withdrawal. Gene Ontology (GO) enrichment analysis for 20 up- and downregulated proteins in the hippocampus revealed that the most enriched GO terms were associated with alterations in energy metabolism, cytoskeleton organization, and oxidative stress response. Our previous proteomic studies indicated that 10-day morphine administration results in significant alterations related to energy metabolism. Moreover, these changes persisted several weeks/months after the cessation of 10-day morphine treatment. We hypothesize that alterations in energy metabolism may be one of the functional consequences of the impaired antioxidant defense system. However, these questions need further investigation.

Author Contributions

Conceptualization, H.U. and J.N.; Methodology, H.U., A.E. and L.H.; Investigation, H.U.; Data Analysis and Interpretation, H.U.; Visualization, H.U.; Project Administration and Supervision, P.S. and J.N.; Writing—Original Draft, H.U. and P.S. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the Czech Science Foundation (grant number 19-03295S) and by the Institute of Physiology (RVO:67985823). This work used instruments provided by C4Sys infrastructure.

Institutional Review Board Statement

The study was approved by the Animal Ethics Committee of the Faculty of Science, Charles University (Prague, Czech Republic), and by the Ministry of Education, Youth and Sports of the Czech Republic (license number MSMT-1479/2019–6).

Data Availability Statement

Data are contained within the article.

Conflicts of Interest

The authors declare no conflict of interest.

Footnotes

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Azevedo Neto J., Constanzini A., De Giorgio R., Lambert D.G., Ruzza C., Calò G. Biased versus partial agonism in the search for safer opioid analgesics. Molecules. 2020;25:3870. doi: 10.3390/molecules25173870. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Paul A.K., Gueven N., Dietis N. Profiling the effects of repetitive morphine administration on motor behavior in rats. Molecules. 2021;26:4355. doi: 10.3390/molecules26144355. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Chen Y., Mestek A., Liu J., Hurley J.A., Yu L. Molecular cloning and functional expression of a mu-opioid receptor from rat brain. Mol. Pharmacol. 1993;44:8–12. doi: 10.1016/0167-0115(94)90214-3. [DOI] [PubMed] [Google Scholar]
  • 4.Pacifici G.M. Metabolism and pharmacokinetics of morphine in neonates: A review. Clinics. 2016;71:474–480. doi: 10.6061/clinics/2016(08)11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Bourova L., Vosahlikova M., Kagan D., Dlouha K., Novotny J., Svoboda P. Long-term adaptation to high doses of morphine causes desensitization of µ-OR- and δ-OR-stimulated G-protein response in forebrain cortex but does not decrease the amount of G-protein alpha subunit. Med. Sci. Monit. 2010;16:260–270. [PubMed] [Google Scholar]
  • 6.Sim L.J., Selley D.E., Dworkin S.I., Childers S.R. Effects of chronic morphine administration on mu opioid receptor-stimulated [35S] GTPgammaS autoradiography in rat brain. J. Neurosci. 1996;16:2684–2692. doi: 10.1523/JNEUROSCI.16-08-02684.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Selley D.E., Liu Q., Childers S.R. Signal transduction correlates of µ opioid agonist intrinsic efficacy: Receptor-stimulated [35S] GTPγS binding in mMOR-CHO cells and rat thalamus. J. Pharm. Exp. Ther. 1998;285:496–505. [PubMed] [Google Scholar]
  • 8.Selley D.E., Cao Q.L., Liu Q., Childers S.R. Effect of sodium on agonist efficacy for G-protein activation in µ-opioid receptor-transfected CHO cells and rat thalamus. Br. J. Pharmacol. 2000;130:987–996. doi: 10.1038/sj.bjp.0703382. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Sim-Selley L.J., Selley D.E., Vogt L.J., Childers S.R., Martin T.J. Chronic heroin self-administration desensitizes mu opioid receptor-activated G-proteins in specific regions of rat brain. J. Neurosci. 2000;20:4555–4562. doi: 10.1523/JNEUROSCI.20-12-04555.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Maher C.E., Selley D.E., Childers S.R. Relationship of mu opioid receptor binding to activation of G-proteins in specific rat brain regions. Biochem. Pharmacol. 2000;59:1395–1401. doi: 10.1016/S0006-2952(00)00272-0. [DOI] [PubMed] [Google Scholar]
  • 11.Maher C.E., Martin T.J., Childers S.R. Mechanisms of mu opioid receptor/G-protein desensitization in brain by chronic heroin administration. Life Sci. 2005;77:1140–1154. doi: 10.1016/j.lfs.2005.03.004. [DOI] [PubMed] [Google Scholar]
  • 12.Ujcikova H., Dlouha K., Roubalova L., Vosahlikova M., Kagan D., Svoboda P. Up-regulation of adenylylcyclases I and II induced by long-term adaptation of rats to morphine fades away 20 days after morphine withdrawal. Biochim. Et Biophys. Acta. 2011;1810:1220–1229. doi: 10.1016/j.bbagen.2011.09.017. [DOI] [PubMed] [Google Scholar]
  • 13.Ujcikova H., Brejchova J., Vosahlikova M., Kagan D., Dlouha K., Sykora J., Merta L., Drastichova Z., Novotny J., Ostasov P., et al. Opioid-receptor (OR) signaling cascades in rat cerebral cortex and model cell lines: The role of plasma membrane structure. Physiol. Res. 2014;63:S165–S176. doi: 10.33549/physiolres.932638. [DOI] [PubMed] [Google Scholar]
  • 14.Ujcikova H., Eckhardt A., Kagan D., Roubalova L., Svoboda P. Proteomic analysis of post-nuclear supernatant and percoll-purified membranes prepared from brain cortex of rats exposed to increasing doses of morphine. Proteome Sci. 2014;12:11. doi: 10.1186/1477-5956-12-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Ujcikova H., Vosahlikova M., Roubalova L., Svoboda P. Proteomic analysis of protein composition of rat forebrain cortex exposed to morphine for 10 days; comparison with animals exposed to morphine and subsequently nurtured for 20 days in the absence of this drug. J. Proteom. 2016;145:11–23. doi: 10.1016/j.jprot.2016.02.019. [DOI] [PubMed] [Google Scholar]
  • 16.Ujcikova H., Cechova K., Jagr M., Roubalova L., Vosahlikova M., Svoboda P. Proteomic analysis of protein composition of rat hippocampus exposed to morphine for 10 days; comparison with animals after 20 days of morphine withdrawal. PLoS ONE. 2020;15:e0231721. doi: 10.1371/journal.pone.0231721. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Ujcikova H., Hejnova L., Eckhardt A., Roubalova L., Novotny J., Svoboda P. Impact of three-month morphine withdrawal on rat brain cortex, hippocampus, striatum and cerebellum: Proteomic and phosphoproteomic studies. Neurochem. Int. 2021;144:104975. doi: 10.1016/j.neuint.2021.104975. [DOI] [PubMed] [Google Scholar]
  • 18.Kim S.Y., Chudapongse N., Lee S.M., Levin M.C., Oh J.T., Park H.J., Ho I.K. Proteomic analysis of phosphotyrosyl proteins in morphine-dependent rat brains. Mol. Brain Res. 2005;133:58–70. doi: 10.1016/j.molbrainres.2004.09.018. [DOI] [PubMed] [Google Scholar]
  • 19.Bierczynska-Krzysik A., Bonar E., Drabik A., Noga M., Suder P., Dylag T., Dubin A., Kotlinska J., Silberring J. Rat brain proteome in morphine dependence. Neurochem. Int. 2006;49:401–406. doi: 10.1016/j.neuint.2006.01.024. [DOI] [PubMed] [Google Scholar]
  • 20.Bierczynska-Krzysik A., Pradeep J.J.P., Silberring J., Kotlinska J., Dylag T., Cabatic M., Lubec G. Proteomic analysis of rat cerebral cortex, hippocampus and striatum after exposure to morphine. Int. J. Mol. Med. 2006;18:775–784. doi: 10.3892/ijmm.18.4.775. [DOI] [PubMed] [Google Scholar]
  • 21.Li K.W., Jimenez C.R., van der Schors R.C., Hornshaw M.P., Schoffelmeer A.N.M., Smit A.B. Intermittent administration of morphine alters protein expression in rat nucleus accumbens. Proteomics. 2006;6:2003–2008. doi: 10.1002/pmic.200500045. [DOI] [PubMed] [Google Scholar]
  • 22.Chen X.L., Lu G., Gong Y.X., Zhao L.C., Chen J., Chi Z.Q., Yang Y.M., Chen Z., Li Q.L., Liu J.G. Expression changes of hippocampal energy metabolism enzymes contribute to behavioral abnormalities during chronic morphine treatment. Cell Res. 2007;17:689–700. doi: 10.1038/cr.2007.63. [DOI] [PubMed] [Google Scholar]
  • 23.Jiang X., Li J., Ma L. Metabolic enzymes link morphine withdrawal with metabolic disorder. Cell Res. 2007;17:741–743. doi: 10.1038/cr.2007.75. [DOI] [PubMed] [Google Scholar]
  • 24.Bodzon-Kułakowska A., Suder P., Mak P., Bierczynska-Krzysik A., Lubec G., Walczak B., Kotlinska J., Lubec G. Proteomic analysis of striatal neuronal cell cultures after morphine administration. J. Sep. Sci. 2009;32:1200–1210. doi: 10.1002/jssc.200800464. [DOI] [PubMed] [Google Scholar]
  • 25.Bodzon-Kułakowska A., Kułakowski K., Drabik A., Moszczynski A., Silberring J., Suder P. Morphinome—A meta-analysis applied to proteomics. Proteomics. 2011;11:5–21. doi: 10.1002/pmic.200900848. [DOI] [PubMed] [Google Scholar]
  • 26.Antolak A., Bodzon-Kułakowska A., Cetnarska E., Pietruszka M., Marszałek-Grabska M., Kotlińska J., Suder P. Proteomic data in morphine addiction versus real protein activity: Metabolic enzymes. J. Cell. Biochem. 2017;118:4323–4330. doi: 10.1002/jcb.26085. [DOI] [PubMed] [Google Scholar]
  • 27.Bodzon-Kułakowska A., Padrtova T., Drabik A., Ner-Kluza J., Antolak A., Kułakowski K., Suder P. Morphinome database—The database of proteins altered by morphine administration—An update. J. Proteom. 2019;190:21–26. doi: 10.1016/j.jprot.2018.04.013. [DOI] [PubMed] [Google Scholar]
  • 28.Drastichova Z., Hejnova L., Moravcova R., Novotny J. Proteomic analysis unveils expressional changes in cytoskeleton- and synaptic plasticity-associated proteins in rat brain six months after withdrawal from morphine. Life. 2021;11:683. doi: 10.3390/life11070683. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Marcus K., Lelong C., Rabilloud T. What room for two-dimensional gel-based proteomics in a shotgun proteomics world? Proteomes. 2020;8:17. doi: 10.3390/proteomes8030017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Schulenberg B., Goodman T.N., Aggeler R., Capaldi R.A., Patton W.F. Characterization of dynamic and steady-state protein phosphorylation using fluorescent phosphoprotein gel stain and mass spectrometry. Electrophoresis. 2004;25:2526–2532. doi: 10.1002/elps.200406007. [DOI] [PubMed] [Google Scholar]
  • 31.Eckhardt A., Jagr M., Pataridis S., Miksik I. Proteomic analysis of human tooth pulp: Proteomics of human tooth. J. Endod. 2014;40:1961–1966. doi: 10.1016/j.joen.2014.07.001. [DOI] [PubMed] [Google Scholar]
  • 32.Jágr M., Eckhardt A., Pataridis S., Foltan R., Mysak J., Miksik I. Proteomic analysis of human tooth pulp proteomes—Comparison of caries-resistant and caries-susceptible persons. J. Proteom. 2016;145:127–136. doi: 10.1016/j.jprot.2016.04.022. [DOI] [PubMed] [Google Scholar]
  • 33.Dodge P.W., Takemori A.E. Effects of morphine, nalnorphine and pentobarbital alone and combination on cerebral glycolytic substrates and cofactors of rats in vivo. Biochem. Pharmacol. 1972;21:287–294. doi: 10.1016/0006-2952(72)90340-1. [DOI] [PubMed] [Google Scholar]
  • 34.Sherman A.D., Mitchell C.L. Effects of morphine and pain on brain intermediary metabolism. Neuropharmacology. 1972;11:871–877. doi: 10.1016/0028-3908(72)90046-9. [DOI] [PubMed] [Google Scholar]
  • 35.Chuang D.M., Hough C., Senatorov V.V. Glyceraldehyde-3-phosphate dehydrogenase, apoptosis, and neurodegenerative diseases. Annu. Rev. Pharmacol. Toxicol. 2005;45:269–290. doi: 10.1146/annurev.pharmtox.45.120403.095902. [DOI] [PubMed] [Google Scholar]
  • 36.Tristan C., Shahani N., Sedlak T.W., Sawa A. The diverse functions of GAPDH: Views from different subcellular compartments. Cell. Signal. 2011;23:317–323. doi: 10.1016/j.cellsig.2010.08.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Landino L.M., Hagedorn T.D., Kennett K.L. Evidence for thiol/disulfide exchange reactions between tubulin and glyceraldehyde-3-phosphate dehydrogenase. Cytoskeleton. 2014;71:707–718. doi: 10.1002/cm.21204. [DOI] [PubMed] [Google Scholar]
  • 38.Kunjithapatham R., Geschwind J.F., Devine L., Boronina T.N., O’Meally R.N., Cole R.N., Torbenson R.S., Ganapathy-Kanniappan S. Occurence of a multimer high-molecular-weight glyceraldehyde-3-phosphate dehydrogenase in human serum. J. Proteome Res. 2015;14:1645–1656. doi: 10.1021/acs.jproteome.5b00089. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Tisdale E.J., Talati N.K., Artalejo C.R., Shisheva A. GAPDH binds Akt to facilitate cargo transport in the early secretory pathway. Exp. Cell Res. 2016;349:310–319. doi: 10.1016/j.yexcr.2016.10.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Lazarev V.F., Guzhova I.V., Margulis B.A. Glyceraldehyde-3-phosphate dehydrogenase is a multifaceted therapeutic target. Pharmaceutics. 2020;12:416. doi: 10.3390/pharmaceutics12050416. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Collel A., Green D.R., Ricci J.E. Novel roles for GAPDH in cell death and carcinogenesis. Cell Death Differ. 2009;16:1573–1581. doi: 10.1038/cdd.2009.137. [DOI] [PubMed] [Google Scholar]
  • 42.Goasdoue K., Awabdy D., Bjorkman S.T., Miller S. Standard loading controls are not reliable for Western blot quantification across brain development or in pathological conditions. Electrophoresis. 2016;37:630–634. doi: 10.1002/elps.201500385. [DOI] [PubMed] [Google Scholar]
  • 43.Repici M., Giorgini M. DJ-1 in Parkinson’s disease: Clinical insights and therapeutic perspectives. J. Clin. Med. 2019;8:1377. doi: 10.3390/jcm8091377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Dos Santos M.C.T., Scheller D., Schulte C., Mesa I.R., Colman P., Bujac S.R., Bell R., Berteau C., Perez L.T., Lachmann I., et al. Evaluation of cerebrospinal fluid proteins as potential biomarkers for early stage Parkinson’s disease diagnosis. PLoS ONE. 2018;13:e0206536. doi: 10.1371/journal.pone.0206536. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Zeng X.S., Geng W.S., Wang Z.Q., Jia J.J. Morphine addiction and oxidative stress: The potential effects of thioredoxin-1. Front. Pharmacol. 2020;11:82. doi: 10.3389/fphar.2020.00082. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Kurutas E.B. The importance of antioxidants which play the role in cellular response against oxidative/nitrosative stress: Current state. Nutr. J. 2016;15:71. doi: 10.1186/s12937-016-0186-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Zhang Y.T., Zheng Q.S., Pan J., Zheng R.L. Oxidative damage of biomolecules in mouse liver induced by morphine and protected by antioxidants. Basic Clin. Pharmacol. Toxicol. 2004;95:53–58. doi: 10.1111/j.1742-7843.2004.950202.x. [DOI] [PubMed] [Google Scholar]
  • 48.Ozmen I., Naziroglu M., Alici H.A., Sahin F., Cengiz M., Eren I. Spinal morphine administration reduces the fatty acid contents in spinal cord and brain by increasing oxidative stress. Neurochem. Res. 2007;32:19–25. doi: 10.1007/s11064-006-9217-5. [DOI] [PubMed] [Google Scholar]
  • 49.Motaghinejad M., Karimian M., Motaghinejad O., Shabab B., Yazdani I., Fatima S. Protective effects of various dosage of curcumin against morphine induced apoptosis and oxidative stress in rat isolated hippocampus. Pharmacol. Rep. 2015;67:230–235. doi: 10.1016/j.pharep.2014.09.006. [DOI] [PubMed] [Google Scholar]
  • 50.Abdel-Zaher A.O., Mostafa M.G., Farghly H.M., Hamdy M.M., Omran G.A., Al-Shaibani N.K.M. Inhibition of brain oxidative stress and inducible nitric oxide synthase expression by thymoquinone attenuates the development of morphine tolerance and dependence in mice. Eur. J. Pharmacol. 2013;702:62–70. doi: 10.1016/j.ejphar.2013.01.036. [DOI] [PubMed] [Google Scholar]
  • 51.Skrabalova J., Drastichova Z., Novotny J. Morphine as a potential oxidative stress-causing agent. Mini Rev. Org. Chem. 2013;10:367–372. doi: 10.2174/1570193X113106660031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Mattei V., Martellucci S., Santilli F., Manganelli V., Garofalo T., Candelise N., Caruso A., Sorice M., Scaccianoce S., Misasi R. Morphine withdrawal modifies prion protein expression in rat hippocampus. PLoS ONE. 2017;12:e0169571. doi: 10.1371/journal.pone.0169571. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Bodzon-Kulakowska A., Suder P., Drabik A., Kotlinska J.H., Silberring J. Constant activity of glutamine synthetase after morphine administration versus proteomic results. Anal. Bioanal. Chem. 2010;398:2939–2942. doi: 10.1007/s00216-010-4244-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Everitt B.J., Robbins T.W. From the ventral to the dorsal striatum: Devolving views of their roles in drug addiction. Neurosci. Biobehav. Rev. 2013;37:1946–1954. doi: 10.1016/j.neubiorev.2013.02.010. [DOI] [PubMed] [Google Scholar]
  • 55.Yager L.M., Garcia A.F., Wunsch A.M., Ferguson S.M. The ins and outs of the striatum: Role in drug addiction. Neuroscience. 2015;301:529–541. doi: 10.1016/j.neuroscience.2015.06.033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Shen S., Jiang X., Li J., Straubinger R.M., Suarez M., Tu C., Duan X., Thompson A.C., Qu J. Large-scale, ion-current-based proteomic investigation of the rat striatal proteome in a model of short- and long-term cocaine withdrawal. J. Proteome Res. 2016;15:1702–1716. doi: 10.1021/acs.jproteome.6b00137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Miquel M., Vazquez-Sanroman D., Carbo-Gas M., Gil-Miravet I., Sanchis-Sequra C., Carulli D., Manzo J., Coria-Avila G.A. Have we been ignoring the elephant in the room? Seven arguments for considering the cerebellum as part of addiction circuitry. Neurosci. Biobehav. Rev. 2016;60:1–11. doi: 10.1016/j.neubiorev.2015.11.005. [DOI] [PubMed] [Google Scholar]
  • 58.Ranjbar H., Soti M., Banazadeh M., Saleki K., Kohlmeier K.A., Shabani M. Addiction and the cerebellum with a focus on actions of opioid receptors. Neurosci. Biobehav. Rev. 2021;131:229–247. doi: 10.1016/j.neubiorev.2021.09.021. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Data are contained within the article.


Articles from Biomedicines are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES